

KEY CONSIDERATIONS

FOR YOUR PATIENT'S INFUSION REFERRAL



1

FIND THE RIGHT INFUSION CENTER

The Entyvio Infusion Center Locator can help patients who have been prescribed Entyvio find the infusion center that most closely matches their needs (eg, location, insurance type, specific amenities).

If your patient needs help with insurance coverage, *EntyvioConnect* offers support throughout the entire insurance approval process, including support with insurance, affordability, and patient education.



EntyvioConnect Information


1-855-ENTYVIO (1-855-368-9846),

or visit EntyvioHCP.com/Access-Support

2

CONTACT THE INFUSION CENTER

After an infusion center has been selected, **contact the center to learn about their specific referral process** and request a referral form. If the infusion center does not have their own referral form, you can use the **Referral Form** located on the Entyvio Infusion Center Locator.



Most centers require information such as:

- Patient name, date of birth, insurance card(s), and contact information
- Diagnosis information, ICD-10-CM codes, and date of last infusion
- Referring physician information, such as office contact information, NPI#, and email address
- Prescription, including name, dosing, frequency, and additional instructions
- Type of access
- Office notes

ICD-10-CM=International Classification of Diseases, Tenth Revision, Clinical Modification; NPI=National Provider Identifier.

KEY CONSIDERATIONS

FOR YOUR PATIENT'S INFUSION REFERRAL



3

SEND THE PRESCRIPTION TO THE INFUSION CENTER

Send a copy of your patient's medical charts documenting their medical history, including current medications, allergies, and chart notes along with the completed prescription. Insurance companies often require documentation of past treatments and test results that support the patient's diagnosis.

4

INFORM THE PATIENT OF TREATMENT REQUIREMENTS

Prior to treatment, Entyvio requires that patients are up to date with all their immunizations.¹



Make patients aware of this **prior to their scheduled treatment** so they can plan for immunizations, if needed.

5

PREPARE PATIENTS FOR THEIR INFUSION TREATMENT

Patients may not know what to expect before and during their infusion treatment. You can refer your patients to the [Patient FAQ](#), located on the Entyvio Infusion Center Locator for additional information.

KEY CONSIDERATIONS

FOR YOUR PATIENT'S INFUSION REFERRAL



IMPORTANT SAFETY INFORMATION

- ENTYVIO (vedolizumab) for injection is contraindicated in patients who have had a known serious or severe hypersensitivity reaction to ENTYVIO or any of its excipients.
- Infusion-related reactions and hypersensitivity reactions including anaphylaxis, dyspnea, bronchospasm, urticaria, flushing, rash, and increased blood pressure and heart rate have been reported. These reactions may occur with the first or subsequent infusions and may vary in their time of onset from during infusion or up to several hours post-infusion. If anaphylaxis or other serious infusion-related or hypersensitivity reactions occur, discontinue administration of ENTYVIO immediately and initiate appropriate treatment.
- Patients treated with ENTYVIO are at increased risk for developing infections. Serious infections have been reported in patients treated with ENTYVIO, including anal abscess, sepsis (some fatal), tuberculosis, salmonella sepsis, Listeria meningitis, giardiasis, and cytomegaloviral colitis. ENTYVIO is not recommended in patients with active, severe infections until the infections are controlled. Consider withholding ENTYVIO in patients who develop a severe infection while on treatment with ENTYVIO. Exercise caution in patients with a history of recurring severe infections. Consider screening for tuberculosis (TB) according to the local practice.
- Progressive multifocal leukoencephalopathy (PML), a rare and often fatal opportunistic infection of the central nervous system (CNS), has been reported with systemic immunosuppressants, including another integrin receptor antagonist. PML is caused by the John Cunningham (JC) virus and typically only occurs in patients who are immunocompromised. One case of PML in an ENTYVIO-treated patient with multiple contributory factors has been reported in the postmarketing setting (e.g., human immunodeficiency virus [HIV] infection with a CD4 count of 300 cells/mm³ and prior and concomitant immunosuppression). Although unlikely, a risk of PML cannot be ruled out. Monitor patients for any new or worsening neurological signs or symptoms. Typical signs and symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. If PML is suspected, withhold dosing with ENTYVIO and refer to a neurologist; if confirmed, discontinue ENTYVIO dosing permanently.
- There have been reports of elevations of transaminase and/or bilirubin in patients receiving ENTYVIO. ENTYVIO should be discontinued in patients with jaundice or other evidence of significant liver injury.
- Prior to initiating treatment with ENTYVIO, all patients should be brought up to date with all immunizations according to current immunization guidelines. Patients receiving ENTYVIO may receive non-live vaccines and may receive live vaccines if the benefits outweigh the risks.
- Most common adverse reactions (incidence $\geq 3\%$ and $\geq 1\%$ higher than placebo): nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, and pain in extremities.

Please see [full Prescribing Information](#), including [Medication Guide](#).

INDICATIONS

Adult Ulcerative Colitis (UC)

ENTYVIO (vedolizumab) is indicated in adults for the treatment of moderately to severely active UC.

Adult Crohn's Disease (CD)

ENTYVIO (vedolizumab) is indicated in adults for the treatment of moderately to severely active CD.

Entyvio for injection: 300 mg vedolizumab in a single-dose vial.

Reference: 1. Entyvio (vedolizumab) prescribing information. Takeda Pharmaceuticals.

If you are a Colorado prescriber, please see the Colorado WAC [disclosure form](#).

ENTYVIO is a trademark of Millennium Pharmaceuticals, Inc., registered with the U.S. Patent and Trademark Office and is used under license by Takeda Pharmaceuticals U.S.A., Inc.

©2022 Takeda Pharmaceuticals U.S.A., Inc. All rights reserved. 1-877-TAKEDA-7 (1-877-825-3327).

US-VED-1414v1.0 04/22